Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Mehdi, R.
Right arrow Articles by Takaoka, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mehdi, R.
Right arrow Articles by Takaoka, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 30:272-275 (2000)
© 2000 Foundation for Promotion of Cancer Research

Expression of Bone Morphogenetic Protein and its Receptors in Osteosarcoma and Malignant Fibrous Histiocytoma

Raza Mehdi, Tominaga Shimizu, Yasuo Yoshimura, Hiroki Gomyo and Kunio Takaoka+

Department of Orthopaedic Surgery, Shinshu University School of Medicine, Asahi, Matsumoto, Nagano, Japan

Background: Bone morphogenetic protein (BMP) activity has been found in cases of malignant fibrous histiocytoma (MFH) and osteosarcoma but only tumors in the latter category show evidence of ossification. The aim of this study was to try to understand this difference by examination of the distribution of BMP and its receptors (BMPR) for this bone inducing protein in these tumors.

Methods: Sections of 11 osteosarcoma and 10 MFH were analyzed immunohistochemically for BMP and BMPRs by use of the avidin–biotin peroxidase method.

Results: Nine out of 11 osteosarcoma cases (80.1%) showed positive staining for both BMP and BMPRs. Two cases of chondroblastic type osteosarcoma did not show any significant staining for BMP and BMPRs. In eight out of 10 MFH cases (80%) there was positive staining for BMP. No immunoreactivity for BMPRs was found in any case of MFH.

Conclusions: MFH does not express BMPRs and this may be the reason why MFH tumors do not ossify, even in the presence of BMP.

+ For reprints and all correspondence: Tominaga Shimizu, Department of Orthopaedic Surgery, Shinshu University School of Medicine, Asahi, Matsumoto, Nagano 390-8621, Japan E-mail: tshimiz@hsp.md.shinshu-u.ac.jpAbbreviations: BMP, bone morphogenetic protein; BMPR, bone morphogenetic protein receptor; MFH, malignant fibrous histiocytoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Vet PatholHome page
T. Akiyoshi, K. Uchida, and S. Tateyama
Expression of Bone Morphogenetic Protein-6 and Bone Morphogenetic Protein Receptors in Myoepithelial Cells of Canine Mammary Gland Tumors
Vet. Pathol., March 1, 2004; 41(2): 154 - 163.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
I Sulzbacher, P Birner, K Trieb, E Pichlbauer, and S Lang
The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter
J. Clin. Pathol., May 1, 2002; 55(5): 381 - 385.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.